Bey­for­tus ap­proved in Chi­na to pro­tect in­fants from RSV; Il­lu­mi­na in­vestor files class ac­tion suit

As­traZeneca and Sanofi’s Bey­for­tus won an ap­proval in Chi­na to pre­vent RSV low­er res­pi­ra­to­ry tract in­fec­tion in new­borns and in­fants dur­ing their first RSV sea­son. US reg­u­la­tors ap­proved the mon­o­clon­al an­ti­body for the same in­di­ca­tion in Ju­ly, and the White House laid out plans in De­cem­ber to make 230,000 more dos­es avail­able to in­fants this month. The drug will be avail­able in Chi­na for the up­com­ing 2024-2025 RSV sea­son, the com­pa­nies said. — Nicole De­Feud­is

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER